查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1976642

人工植入市場：依植入類型、技術、材質和最終用戶分類－2026-2032年全球預測

Artificial Implants Market by Implant Type, Technology, Material Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人工植入市場價值將達到 472.4 億美元，到 2026 年將成長至 511.6 億美元，到 2032 年將達到 834.4 億美元，複合年成長率為 8.46%。

主要市場統計數據
基準年 2025 472.4億美元
預計年份：2026年 511.6億美元
預測年份 2032 834.4億美元
複合年成長率 (%) 8.46%

臨床、監管和製造趨勢構成了一個策略框架，塑造著植入式醫療設備。

人口壓力、技術突破和醫療模式的變革正推動人工植入領域經歷持續的結構性變革時期。臨床醫生擴大使用兼具機械功能和生物相容性的植入式裝置來治療慢性病和退化性疾病。相關人員正積極回應，加大對材料科學、積層製造和互聯功能的投入。隨著醫療機構和患者對能夠降低再次手術率、縮短恢復時間和實現遠端監測的植入的需求日益成長，產品開發正從單一學科工程轉向融合生物材料、軟體和外科技術的跨學科項目。

對以患者主導的護理、積層製造技術、智慧設備整合和監管進步如何重塑植入開發進行詳細、全面的分析。

近年來，植入領域的進展反映了變革性的改變，重新定義了產品生命週期和醫療服務模式。首先，以患者為中心的照護模式和完善的報銷機制，使得人們更加關注對患者至關重要的療效指標，例如功能性、耐用性和生活品質。因此，能夠最大限度地減少併發症並促進更快康復的材料和器械結構，已成為設計重點。其次，積層製造和先進的表面處理技術已從原型製作走向大規模生產，從而能夠製造出形狀更複雜的植體、植入的患者特異性植體，並增強骨整合性能。第三，數位技術的融合加速了智慧植入的應用，這些植體整合了遙測、感測器和封閉回路型刺激功能。這使得植體的價值不再局限於機械正畸，而是擴展到持續的生理管理。

基於證據評估貿易壁壘上升對採購、製造地策略、定價趨勢和供應商風險管理的影響。

美國貿易政策調整引發的關稅措施正對全球植入供應鏈和商業策略產生連鎖反應。特定零件和原料進口關稅的提高直接增加了依賴海外供應商的製造商的到岸成本，迫使採購團隊重新審視其供應商組合，加快在地採購，或對替代供應商進行認證。為此，一些製造商優先考慮庫存緩衝和雙重採購策略，以確保手術用品供應的連續性；而另一些製造商則考慮對易受關稅波動影響的關鍵零件進行垂直整合。

將設備分類、醫療環境、材料選擇和底層技術與臨床要求和商業化途徑連結起來的多維分割分析。

詳細的細分分析揭示了不同類型植入、最終用戶、材料和底層技術如何影響其開發重點和應用模式。在植入分類系統中，其範圍涵蓋循環系統器械，例如心臟瓣膜、心律調節器、支架和血管移植物。心臟瓣膜進一步細分為生物瓣膜和機械瓣膜，支架則根據其在冠狀動脈和周邊血管中的應用進行區分。人工電子耳神經刺激設備、整形外科、視網膜和泌尿系統植入各有不同的臨床需求。整形外科解決方案進一步分為骨板和螺絲釘、關節重建、脊椎融合手術和創傷固定，其中關節重建包括髖關節、膝關節和肩關節手術。每個類別對耐用性、影像相容性、動態性能和外科醫生工作流程都有不同的要求。

區域情報概述：本節闡述了不同的管理體制、支付模式和製造能力如何影響全球市場引進和商業化策略。

區域趨勢對產品開發重點、監管策略和商業化計畫有顯著影響。在美洲，支付模式、醫院整合趨勢以及完善的臨床研究基礎設施正在推動對高品質、功能豐富的植入以及支援療效評估和遠端追蹤的數位化平台的需求。美國是先進臨床試驗和下一代技術早期應用的中心，這通常為技術向該地區其他市場的擴散創造了途徑。

企業環境評估，解釋了現有產品組合、敏捷創新者和策略夥伴關係如何結合起來，加速醫療設備的轉換和商業性規模。

植入產業的企業行為體現了在維持現有業務和追求顛覆性創新之間的平衡。成熟的醫療設備製造商傾向於對成熟平台進行漸進式改進，最佳化生產效率，透過強化塗層和模組化設計延長產品生命週期，並利用現有的應用經驗累積證據。同時，新興企業和專業技術公司則專注於突破性材料、生物可吸收結構、用於特異性患者的積層製造技術，以及能夠實現遠端監測和封閉回路型治療的嵌入式數位功能。

為經營團隊提供實用指導，透過調整證據產生和供應網路的韌性和技術模組化，確保臨床應用和商業性永續性。

產業領導者應採取積極主動的方式，整合臨床證據的建立、供應鏈韌性和技術差異化。優先考慮模組化產品架構和可互通的軟體框架，可實現分階段更新，而無需更換整個平台。此外，對來自註冊登記和連網設備的資料流的投資，有助於履行基於價值的合約和滿足上市後監測要求。為降低供應商集中風險，企業應認證關鍵合金、聚合物和電子子系統的替代供應商，並建立清晰的供應商績效指標和快速檢驗流程。

嚴謹的混合方法研究框架結合了相關人員訪談、監管和技術分析以及檢驗，檢驗業界考察和策略指導。

本執行摘要的研究結合了對關鍵相關人員的訪談、系統的二手資訊回顧以及有針對性的技術分析，旨在建立植入領域的全面而全面的整體情況。主要資訊來源包括與來自不同專科的臨床醫生、來自不同醫療機構的採購經理、監管事務專業人員以及參與材料和製造的技術專家的對話。這些質性見解輔以對監管指導文件、臨床試驗註冊資訊、專利申請和同行評審文獻的系統性回顧，以檢驗有關安全性、有效性和技術成熟度的說法。

簡明扼要地總結道，多學科創新、供應韌性和實證策略決定了植入領域的競爭優勢。

人工植入正進入一個關鍵階段，跨學科創新、監管監管和穩健的製造系統將決定其成敗。尖端材料、積層製造和數位化整合技術的融合，不僅創造出能夠恢復功能，還能提供持續臨床洞察的植入物，改變了人們對植入的期望。同時，供應鏈的脆弱性、關稅帶來的成本壓力以及不同地區監管路徑的差異，都要求企業採用靈活的採購模式和積極主動的監管策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人工植入市場（以植入類型分類）

  • 心血管系統
    • 心臟瓣膜
      • 生物瓣膜
      • 機械的
    • 心律調節器
    • 支架
      • 冠狀動脈
      • 外圍
    • 血管移植
  • 人工電子耳
  • 美麗
  • 牙科
  • 神經刺激設備
  • 整形外科
    • 骨板和螺絲
    • 關節重建
      • 髖關節
      • 膝蓋
      • 肩膀
    • 脊椎融合手術
    • 創傷固定
  • 視網膜
  • 泌尿系統

第9章：人工植入市場：依技術分類

  • 3D列印
  • 生物活性塗層
  • 藥物釋放型型
  • 微創
  • 智慧植入

第10章：人工植入市場：依材料類型分類

  • 合金
  • 可生物分解材料
  • 陶瓷
  • 聚合物
  • 鈦

第11章：人工植入市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 居家醫療
  • 醫院

第12章 人工植入市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：人工植入市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 人工植入市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國人工植入市場

第16章：中國人工植入市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Advanced Bionics Corporation by Sonova Holding AG
  • Aesculap Implant Systems by B. Braun Medical, Inc.
  • Bicon, LLC
  • Boston Scientific Corporation
  • Cochlear Limited
  • DENTSPLY SIRONA Inc.
  • DIOPTEX GmbH
  • Exactech Inc.
  • EyeYon
  • FCI Ophthalmics, Inc.
  • GS Solutions, Inc.
  • Johnson & Johnson
  • KeraMed, Inc.
  • Medical Device Business Services, Inc. by Johnson & Johnson
  • Medtronic plc
  • Nobel Biocare Services AG
  • NuVasive, Inc.
  • Smith & Nephew Plc
  • Straumann Holding AG
  • Stryker Corporation
  • Terumo Corporation
  • TTK Healthcare Limited
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-69324464D1A9

The Artificial Implants Market was valued at USD 47.24 billion in 2025 and is projected to grow to USD 51.16 billion in 2026, with a CAGR of 8.46%, reaching USD 83.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.24 billion
Estimated Year [2026] USD 51.16 billion
Forecast Year [2032] USD 83.44 billion
CAGR (%) 8.46%

A strategic framing of clinical, regulatory, and manufacturing dynamics shaping the future of implantable medical devices across disciplines

The landscape of artificial implants is experiencing a period of sustained structural change driven by demographic pressures, technological breakthroughs, and shifting care models. Clinicians increasingly treat chronic and degenerative conditions with implantable devices that blend mechanical function with biological integration, and industry stakeholders are responding by investing in materials science, additive manufacturing, and connected-device capabilities. As institutions and patients demand implants that reduce revision rates, shorten recovery times, and enable remote monitoring, product development has shifted away from single-discipline engineering toward multidisciplinary programs that combine biomaterials, software, and surgical technique.

Parallel to clinical advances, regulatory agencies have updated guidance to reflect novel device pathways and greater emphasis on post-market surveillance, which together inform design, testing, and commercial strategies. Supply chain dynamics, including sourcing of specialty alloys, polymer formulations, and precision components, are increasingly relevant to manufacturers' ability to deliver consistent quality at scale. In this context, stakeholders from hospital systems to device startups must navigate an environment where clinical evidence, manufacturing robustness, and digital integration determine long-term adoption. This executive summary synthesizes these interdependent forces to provide leaders with a concise, evidence-based view of the trends shaping innovation and market behavior across implant types, end users, materials, technologies, regions, and corporate actors.

A detailed synthesis of patient-driven care, additive manufacturing, smart device integration, and regulatory evolution reshaping implant development

The evolution of the implant sector in recent years reflects transformative shifts that are redefining product lifecycles and care delivery. First, patient-centric care models and bundled reimbursement frameworks have increased focus on outcomes that matter to patients, such as functionality, longevity, and quality of life; consequently, design priorities have moved toward materials and device architectures that minimize complications and support faster rehabilitation. Second, additive manufacturing and sophisticated surface engineering techniques have transitioned from prototyping tools to production-ready methods, enabling more complex geometries, patient-specific implants, and enhanced osseointegration properties. Third, digital convergence has accelerated the deployment of smart implants that incorporate telemetry, sensors, or closed-loop stimulation, thereby extending device value beyond mechanical correction to continuous physiologic management.

Regulatory and clinical evidence expectations have also changed, emphasizing real-world data collection and life-cycle risk management. As a result, manufacturers are investing in registries, remote monitoring platforms, and adaptive trial designs. Meanwhile, materials innovation - including bioactive coatings, resorbable polymers, and hybrid composites - is unlocking new therapeutic possibilities while challenging legacy manufacturing processes. Finally, strategic partnerships among device firms, contract manufacturers, and health systems are becoming more prevalent, as each seeks to de-risk development, expand clinical access, and accelerate time-to-implant. Taken together, these shifts are creating an environment where agility, cross-disciplinary expertise, and robust post-market intelligence determine competitive advantage.

An evidence-based appraisal of how elevated trade barriers are influencing procurement, manufacturing location strategy, pricing dynamics, and supplier risk management

Tariff actions originating from trade policy adjustments in the United States have collateral effects across global implant supply chains and commercial strategies. Increased import duties on select components or raw materials directly raise landed costs for manufacturers reliant on overseas suppliers, prompting procurement teams to revisit supplier portfolios and to accelerate local sourcing or qualification of alternate vendors. In response, some manufacturers prioritize inventory buffers and dual sourcing strategies to maintain surgical supply continuity, while others explore vertical integration for critical components that are sensitive to tariff volatility.

Beyond immediate cost implications, tariffs influence longer-term strategic decisions about plant location, contract manufacturing relationships, and capital allocation. For example, manufacturers evaluating capacity expansion may factor in tariff-related operating cost differentials when assessing nearshoring versus maintaining low-cost offshore production. Tariffs can also alter product pricing dynamics in healthcare systems that already face constrained reimbursement, potentially shifting negotiations between manufacturers and providers and accelerating demand for lower-cost alternative technologies. Additionally, regulatory approval timelines and conformity assessments for components sourced from new suppliers require careful management to avoid implant availability disruptions.

Importantly, tariffs interact with non-tariff trade measures and export controls, amplifying complexity for companies operating across multiple jurisdictions. Therefore, companies must consider both macroeconomic trade policy trends and granular supplier risk when planning production and commercialization, balancing cost mitigation with the need to preserve quality, clinical performance, and regulatory compliance.

A multidimensional segmentation analysis linking device classes, care settings, material choices, and enabling technologies to clinical requirements and commercialization pathways

A granular segmentation lens reveals how development priorities and adoption patterns diverge across implant types, end users, materials, and enabling technologies. When viewed through implant taxonomy, the universe spans cardiovascular devices such as heart valves, pacemakers, stents, and vascular grafts, with heart valves subdivided by bioprosthetic and mechanical designs and stents differentiated into coronary and peripheral indications. Cochlear, cosmetic, dental, neurostimulator, orthopedic, retinal, and urological implants present distinct clinical requirements, while orthopedic solutions further divide into bone plates and screws, joint replacement, spinal fusion, and trauma fixation, with joint replacement encompassing hip, knee, and shoulder procedures. Each category imposes different demands on durability, imaging compatibility, biomechanical performance, and surgeon workflow.

End-user segmentation highlights divergent procurement and care pathways, from ambulatory surgical centers and clinics to home care environments and hospitals. These settings vary in procedural volume, capital equipment availability, and decision-making timelines, which in turn affect product design, packaging, and support services. Material selection likewise differentiates product strategies; alloys continue to underpin load-bearing implants, biodegradable materials enable transient scaffolds and drug delivery applications, ceramics offer wear resistance in articulating surfaces, polymers provide design flexibility and radiolucency, and titanium remains the standard for many load-bearing orthopaedic and craniofacial indications. Technology segmentation illuminates the impact of additive manufacturing for patient-specific geometries, bioactive coatings for surface integration, drug-eluting platforms for infection or restenosis control, minimally invasive approaches that reduce tissue trauma, and smart implants that deliver sensing or therapy modulation. Integrating these segmentation dimensions allows stakeholders to prioritize R&D investments, tailor regulatory strategies, and align commercialization plans with the clinical environments that will ultimately use and support the implants.

A regional intelligence overview explaining how distinct regulatory regimes, payer models, and manufacturing capabilities shape adoption and commercialization strategies across global markets

Regional dynamics significantly influence product development priorities, regulatory strategy, and commercialization planning. In the Americas, payer models, hospital consolidation trends, and a strong clinical research infrastructure shape demand for high-evidence, feature-rich implants and for digital platforms that support outcomes measurement and remote follow-up. The United States serves as a hub for advanced clinical trials and early adoption of next-generation technologies, which often creates a technology diffusion pathway to other markets in the hemisphere.

In the Europe, Middle East & Africa region, heterogeneity in reimbursement frameworks and regulatory harmonization efforts produce a complex environment for market entry. European regulatory modernization and an emphasis on clinical equivalence or added-value demonstrate the importance of robust post-market data and health-economics evidence. Markets in the Middle East and Africa present pockets of rapid infrastructure investment alongside access challenges, making tiered product strategies and local partnerships valuable for adoption.

The Asia-Pacific region presents a mix of high-volume surgical markets, rapid adoption of cost-effective innovations, and emergent centers of manufacturing and R&D excellence. Diverse regulatory maturation across countries requires nuanced entry strategies, while growing domestic capabilities in materials and additive manufacturing present opportunities for regional supply chain optimization. Across all regions, demographic trends, surgical capacity expansion, and digital health integration drive both common and region-specific priorities for implant developers and their commercial partners.

A corporate landscape appraisal describing how incumbent portfolios, nimble innovators, and strategic partnerships are combining to accelerate device translation and commercial scale-up

Corporate behavior in the implant sector reflects a balancing act between sustaining legacy franchises and pursuing disruptive innovation. Established device manufacturers often focus on incremental improvement to proven platforms, optimizing manufacturing efficiency, extending device lifecycles through enhanced coatings or modularity, and leveraging installed bases for evidence generation. At the same time, emerging companies and specialized technology firms concentrate on breakthrough materials, bioresorbable constructs, additive manufacturing for patient-specific devices, and embedded digital functionality that enables remote monitoring or closed-loop therapies.

Across the competitive landscape, collaboration between original equipment manufacturers, contract development and manufacturing organizations, clinical research networks, and technology providers accelerates translation from concept to clinic. Strategic alliances frequently encompass co-development agreements, licensing of intellectual property, and distribution partnerships that expand geographic reach. Investment trends indicate sustained interest from corporate venture groups and strategic investors in early-stage technologies that promise differentiation through clinical performance or cost-efficiency. In parallel, the role of contract manufacturers and precision component suppliers has become more prominent as companies seek to scale complex production processes while maintaining regulatory compliance and traceability. Taken together, these dynamics underscore the need for a coherent corporate strategy that aligns R&D priorities, manufacturing capabilities, and go-to-market execution to capture long-term value.

Action-oriented guidance for executives to align evidence generation, supply resilience, and technology modularity to secure clinical adoption and commercial durability

Industry leaders should adopt a proactive posture that aligns clinical evidence generation, supply chain resilience, and technology differentiation. Prioritizing modular product architectures and interoperable software frameworks enables incremental updates without full platform replacement, and investing in registries and connected-device data streams supports value-based contracting and post-market surveillance requirements. To mitigate supplier concentration risk, companies should qualify alternate sources for critical alloys, polymers, and electronic subsystems while developing clear supplier performance metrics and expedited validation pathways.

In R&D, integrating materials science with computational modeling and additive manufacturing can shorten design cycles and enable patient-specific solutions that reduce revision rates. Commercial teams should tailor go-to-market strategies to the procedural setting, recognizing that hospitals, ambulatory surgical centers, clinics, and home care pathways have distinct purchasing drivers and post-procedural support needs. Regulatory engagement must begin early and continue throughout product life cycles, emphasizing human factors, durability testing, and real-world performance data to streamline approvals and reimbursement discussions. Finally, leaders should evaluate strategic partnerships and M&A as levers to access complementary capabilities, accelerate market entry, or secure manufacturing capacity, ensuring that cultural and operational integration plans are developed to capture intended synergies.

A rigorous mixed-methods research framework combining stakeholder interviews, regulatory and technical analysis, and triangulation to validate sector insights and strategic guidance

The research underpinning this executive summary combines primary stakeholder interviews, systematic secondary-source review, and targeted technical analysis to create a robust picture of the implant sector. Primary inputs included conversations with clinicians across specialties, procurement leaders from diverse care settings, regulatory affairs professionals, and technology experts involved in materials and manufacturing. These qualitative insights were complemented by a structured review of regulatory guidance documents, clinical trial registries, patent filings, and peer-reviewed literature to validate claims around safety, efficacy, and technological readiness.

Technical assessment incorporated materials characterization literature, manufacturing case studies, and analysis of device architectures to identify trends in additive manufacturing, coatings, and embedded electronics. Supply chain analysis leveraged trade flow data and public procurement documentation to assess sourcing risks and potential tariff impacts. Where applicable, scenario-based analysis was used to explore how changes in policy, reimbursement, or manufacturing cost profiles might affect strategic choices. Throughout the research process, findings were triangulated across multiple sources to mitigate bias, and expert review panels provided challenge and validation to key conclusions and recommendations.

A concise closing synthesis underscoring how multidisciplinary innovation, supply resilience, and evidence strategies will determine competitive positioning in the implant sector

Artificial implants are entering a phase where multidisciplinary innovation, regulatory vigilance, and resilient manufacturing will determine success. The interplay between advanced materials, additive manufacturing, and digital integration is creating devices that not only restore function but also provide continuous clinical insight, shifting expectations for what implants can deliver. At the same time, supply chain fragility, tariff-induced cost pressures, and divergent regional regulatory pathways require companies to adopt flexible sourcing models and proactive regulatory strategies.

Strategically, organizations that invest in evidence generation, design for manufacturability, and interoperable digital ecosystems will be better positioned to meet clinicians' and patients' evolving expectations. Collaboration across the value chain-from raw material suppliers to health systems-will be essential to accelerate safe deployment and to demonstrate value in real-world settings. In conclusion, the implant sector's near-term trajectory rewards those who combine technical excellence with operational discipline and clear clinical partnerships to drive sustainable adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Implants Market, by Implant Type

  • 8.1. Cardiovascular
    • 8.1.1. Heart Valves
      • 8.1.1.1. Bioprosthetic
      • 8.1.1.2. Mechanical
    • 8.1.2. Pacemakers
    • 8.1.3. Stents
      • 8.1.3.1. Coronary
      • 8.1.3.2. Peripheral
    • 8.1.4. Vascular Grafts
  • 8.2. Cochlear
  • 8.3. Cosmetic
  • 8.4. Dental
  • 8.5. Neurostimulators
  • 8.6. Orthopedic
    • 8.6.1. Bone Plates & Screws
    • 8.6.2. Joint Replacement
      • 8.6.2.1. Hip
      • 8.6.2.2. Knee
      • 8.6.2.3. Shoulder
    • 8.6.3. Spinal Fusion
    • 8.6.4. Trauma Fixation
  • 8.7. Retinal
  • 8.8. Urological

9. Artificial Implants Market, by Technology

  • 9.1. 3D Printing
  • 9.2. Bioactive Coatings
  • 9.3. Drug-Eluting
  • 9.4. Minimally Invasive
  • 9.5. Smart Implants

10. Artificial Implants Market, by Material Type

  • 10.1. Alloys
  • 10.2. Biodegradable Materials
  • 10.3. Ceramics
  • 10.4. Polymers
  • 10.5. Titanium

11. Artificial Implants Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Home Care
  • 11.4. Hospitals

12. Artificial Implants Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Artificial Implants Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Artificial Implants Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Artificial Implants Market

16. China Artificial Implants Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Advanced Bionics Corporation by Sonova Holding AG
  • 17.7. Aesculap Implant Systems by B. Braun Medical, Inc.
  • 17.8. Bicon, LLC
  • 17.9. Boston Scientific Corporation
  • 17.10. Cochlear Limited
  • 17.11. DENTSPLY SIRONA Inc.
  • 17.12. DIOPTEX GmbH
  • 17.13. Exactech Inc.
  • 17.14. EyeYon
  • 17.15. FCI Ophthalmics, Inc.
  • 17.16. GS Solutions, Inc.
  • 17.17. Johnson & Johnson
  • 17.18. KeraMed, Inc.
  • 17.19. Medical Device Business Services, Inc. by Johnson & Johnson
  • 17.20. Medtronic plc
  • 17.21. Nobel Biocare Services AG
  • 17.22. NuVasive, Inc.
  • 17.23. Smith & Nephew Plc
  • 17.24. Straumann Holding AG
  • 17.25. Stryker Corporation
  • 17.26. Terumo Corporation
  • 17.27. TTK Healthcare Limited
  • 17.28. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL IMPLANTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL IMPLANTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOPROSTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOPROSTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOPROSTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PACEMAKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PACEMAKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PACEMAKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COCHLEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COCHLEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COCHLEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COSMETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COSMETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COSMETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY NEUROSTIMULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY NEUROSTIMULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY NEUROSTIMULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BONE PLATES & SCREWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BONE PLATES & SCREWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BONE PLATES & SCREWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY KNEE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY KNEE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SHOULDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SPINAL FUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SPINAL FUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SPINAL FUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY RETINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY RETINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY RETINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY UROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY 3D PRINTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY 3D PRINTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY 3D PRINTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOACTIVE COATINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOACTIVE COATINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIOACTIVE COATINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DRUG-ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DRUG-ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY DRUG-ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SMART IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SMART IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY SMART IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ALLOYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ALLOYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY ALLOYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIODEGRADABLE MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIODEGRADABLE MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY BIODEGRADABLE MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CERAMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CERAMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CERAMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TITANIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL ARTIFICIAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY IMPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ARTIFICIAL IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)